Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib DDI Study with Transporter Substrates
NCT05768360Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of savolitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoints: Area Under Concentration-time Curve from zero to infinity, Area under the concentration-curve from zero to the last quantifiable concentration and 3 more. Started Apr 2023; status: completed.
02
Drugs
savolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05768360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05768360.